Complete Story


CDC Advisers Reconvene to Weigh Next Steps on Johnson & Johnson Vaccine

Rare, serious blood clots are creating fear among many

A federal vaccine advisory committee is reconvening Friday to discuss next steps for Johnson & Johnson's coronavirus vaccine after health officials recommended last week that states pause use while six U.S. cases of a rare and severe type of blood clot were reviewed.

That independent expert panel, the Advisory Committee on Immunization Practices, last met April 14. It reviewed the decision made the day before by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) to recommend a temporary halt n giving the vaccine following reports of a handful of blood clots among the more than 7.5 million people who had been inoculated at that time.

The panel said at that meeting it needed more data on the risks, cause and frequency of the rare brain blood clots before recommending a lift to the pause or other steps, such as restrictions based on age or gender.

Please select this link to read the complete article from The Washington Post.

Printer-Friendly Version